.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
This landmark randomized trial tested early integration of palliative care alongside standard oncology treatment in patients with newly diagnosed metastatic non-small-cell lung cancer. Patients referred early to palliative care had better quality of life and mood than those receiving usual oncologic care alone. They were also less likely to receive aggressive end-of-life interventions, and the study reported longer median survival in the early-palliative-care group. The key clinical message is that palliative care is not synonymous with stopping active cancer treatment. It can begin at diagnosis and run in parallel with disease-directed therapy, helping patients define goals, manage symptoms, address distress, and make decisions as the illness evolves. For HCPs, this supports earlier conversations rather than waiting until a patient has exhausted options or becomes critically unwell. The paper aligns directly with the conference’s emphasis on early palliative integration in lung cancer and on goals-of-care conversations in advanced respiratory disease. It also provides a useful framework for multidisciplinary practice, where pulmonology, oncology, palliative medicine, nursing, and family caregivers contribute to a coherent plan of care.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
This landmark randomized trial tested early integration of palliative care alongside standard oncology treatment in patients with newly diagnosed metastatic non-small-cell lung cancer. Patients referred early to palliative care had better quality of life and mood than those receiving usual oncologic care alone. They were also less likely to receive aggressive end-of-life interventions, and the study reported longer median survival in the early-palliative-care group. The key clinical message is that palliative care is not synonymous with stopping active cancer treatment. It can begin at diagnosis and run in parallel with disease-directed therapy, helping patients define goals, manage symptoms, address distress, and make decisions as the illness evolves. For HCPs, this supports earlier conversations rather than waiting until a patient has exhausted options or becomes critically unwell. The paper aligns directly with the conference’s emphasis on early palliative integration in lung cancer and on goals-of-care conversations in advanced respiratory disease. It also provides a useful framework for multidisciplinary practice, where pulmonology, oncology, palliative medicine, nursing, and family caregivers contribute to a coherent plan of care.
Today
The phase 3 ACACIA-HCM trial reveals that aficamten improves cardiac structure, diastolic relaxation, functional capacity, and symptom burden in symptomatic nonobstructive hypertrophic cardiomyopathy, marking a major milestone in targeted myosin inhibition.
6 days back
A clinical study shows that automated breast ultrasound paired with artificial intelligence accurately classifies BIRADS 3-4 lesions, reaching 95% sensitivity and 79% specificity. This diagnostic advance promises to reduce unnecessary core needle biopsies and refine clinical workflows in breast imaging.
3 weeks back
Researchers have engineered freestanding hierarchical-porous BCZT thin films that resist cracking and enhance ultrasonic energy harvesting in soft tissue. Achieving high piezoelectric output and acoustic matching, this lead-free material offers transformative potential for implantable bioelectronics.
6 days back
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
3 weeks back
A breakthrough study identifies the Klotho/PKCα/CUX1/SPARC/TGFβ-RII axis as a critical driver of podocyte mitochondrial injury and ferroptosis in diabetic kidney disease, unveiling promising molecular targets to halt renal disease progression.
6 days back
